Enanta: Filed Patent Infringement Suit Against Pfizer Over Paxlovid
2022年6月22日 - 6:47AM
Dow Jones News
By Stephen Nakrosis
Biotechnology company Enanta Pharmaceuticals Inc. on Tuesday
said it filed a patent infringement suit against Pfizer Inc.,
seeking damages in the manufacture, use and sale of Paxlovid.
Enanta said it received a patent earlier this month based on a
July 2020 patent application "describing coronavirus protease
inhibitors invented by Enanta scientists."
Paxlovid has been used to treat patients suffering from
Covid-19. Enanta said it "does not intend to seek an injunction or
take other action in this litigation that would impede the
production, sale or distribution of Paxlovid." The company said it
"seeks fair compensation for Pfizer's use of a coronavirus 3CL
protease inhibitor claimed" in its patent.
The suit was filed in the U.S. District Court for the District
of Massachusetts, Enanta said.
Pfizer didn't immediately respond to a request for comment.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 21, 2022 17:32 ET (21:32 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
過去 株価チャート
から 3 2024 まで 4 2024
Pfizer (NYSE:PFE)
過去 株価チャート
から 4 2023 まで 4 2024
